西南医科大学附属医院
Affiliated Hospital of Southwest Medical University
在本站收录的 53 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
西南医科大学附属医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma15 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma97 篇牵头论文
- 胃癌Stomach cancer39 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma20 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 尤文肉瘤Ewing sarcoma3 篇牵头论文
- 多发性骨髓瘤Multiple myeloma10 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 再生障碍性贫血Aplastic anaemia2 篇牵头论文
- β 地中海贫血Beta thalassaemia3 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis3 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 肝包虫病Hepatic echinococcosis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- Alport 综合征Alport syndrome1 篇牵头论文
- IgA 肾病IgA nephropathy3 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文
未列出的收录疾病:肝母细胞瘤、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文15
- Serum HOTTIP expression is upregulated in nasopharyngeal carcinoma patients and predicts poor prognosis.
- Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment.
- Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT for tumor staging and primary tumor volume delineation in patients with nasopharyngeal carcinoma.
- Development of a neoadjuvant chemotherapy efficacy prediction model for nasopharyngeal carcinoma integrating magnetic resonance radiomics and pathomics: a multi-center retrospective study.
- Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma.
- Comprehensive analysis revealed P4Hs as new biomarkers for prognosis and immunotherapy in head and neck cancer.
- Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy.
- Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial.
- Long non-coding RNA HOTTIP exerts an oncogenic function by regulating HOXA13 in nasopharyngeal carcinoma.
- HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-2.
- Development of a Radiotherapy Localisation Computed Tomography-Based Radiomic Model for Predicting Survival in Patients With Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Following Induction Chemotherapy.
- Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.
- Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis.
- Minimally Invasive Surgery for Early-Stage Nasopharyngeal Carcinoma.
- FANCD2 knockdown with shRNA interference enhances the ionizing radiation sensitivity of nasopharyngeal carcinoma CNE-2 cells.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)9
- A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma
- DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning
- Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.
- The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma
- HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-2
- Interim Results of a Prospective, Randomized, Multicenter, Phase 3 Study of the Efficacy of Increasing the Cycles of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma
- The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–2019
- Correlation Between Immune Function Status and EBV DNA in Patients with Nasopharyngeal Carcinoma and Their Influence on Prognosis
- EBV-positive LMP1-mediated Signal Pathway in Nasopharyngeal Carcinoma
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文12
- SND1-SMARCA5 interaction strengthened by PIM promotes the proliferation, metastasis, and chemoresistance of esophageal squamous cell carcinoma.
- Esophageal cancer and precancerous lesions: focus on resident bacteria and fungi.
- Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances.
- ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma.
- Expression of Polyadenylate-binding Protein Cytoplasmic 1 (PABPC1) in Combination With RAD51 as Prognostic Biomarker in Patients Who Underwent Postoperative Chemotherapy for Esophageal Squamous Cell Carcinoma.
- Metastasis to recurrent laryngeal nerve lymph nodes as a predictor of cervical lymph node metastasis in esophageal squamous cell carcinoma.
- Engrailed 2 triggers the activation of multiple phosphorylation-induced signaling pathways in both transcription-dependent and -independent manners.
- Hypoxia-responsive lncRNA G077640 promotes ESCC tumorigenesis via the H2AX-HIF1α-glycolysis axis.
- Circ_0024108 promotes the progression of esophageal cancer cells.
- Erianin Exerts Antineoplastic Effects on Esophageal Squamous Cell Carcinoma Cells by Activating the cGMP-PKG Signaling Pathway.
- KDM2A plays a dual role in regulating the expression of malignancy-related genes in esophageal squamous cell carcinoma.
- CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)12
- 253. MICROBIOTA ENTEROTOXIGENIC BACTEROIDES FRAGILIS (ETBF) PROMOTES ESCC TUMOR FORMATION, MIGRATION, AND INVASION BY PROMOTING EMT AND ACTIVATING TLR4/NF-κB SIGNALING PATHWAY
- 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Long-term survival of esophageal squamous cell carcinoma after surgical treatment in a large-scale retrospective study from a single cancer center
- Overexpression of CXCL5 promotes proliferation and infiltration of esophageal squamous cell carcinoma
- 629 IRRADIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELLS INDUCED THE INCREASE OF TREG BY TGF-β
- 631 CLINICAL APPLICATION VALUE OF THE SYSTEMIC-IMMUNE-INFLAMMATION-INDEX FOR PREDICTING SURVIVAL IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA UNDERGOING CHEMORADIOTHERAPY OR RADIOTHERAPY
- 685 THE IMPACT OF ADJUVANT THERAPY ON SURVIVAL FOR NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PROPENSITY SCORE MATCHED ANALYSIS
- 695 METASTASIS OF THORACIC RECURRENT LARYNGEAL NERVE LYMPH NODE AS PREDICTOR FOR CERVICAL LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- KDM6B Promotes ESCC Cell Proliferation and Metastasis by Facilitating C/EBPβ Transcription
- Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 97 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
泸州有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2021-09
- 登记号
- NCT05047510
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心泸州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文97
- Synthesis and antitumor evaluation of glycyrrhetinic acid-dithiocarbamate hybrids.
- Prediction model establishment of prognosis factors for distant metastasis of hepatocellular carcinoma based on the SEER database.
- WWP2-induced inhibition of hepatocellular carcinoma cellular senescence via the ubiquitination and degradation of p21.
- Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.
- Icaritin-Loaded Liposomes Mediated by Hyaluronic Acid Promoted the Anti-Proliferation and Senescence in Huh7 Cells.
- ANG secretion predisposes endothelial cells toward angiogenesis in FIN56-induced ferroptotic hepatocellular carcinoma via the BMP6/ID1 signaling pathway.
- ARIH2 serves as a potential prognostic biomarker for hepatocellular carcinoma associated with immune infiltration and ferroptosis.
- Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.
- Machine Learning-Based Integration of Single-Cell and Bulk Transcriptome Reveals Coagulation Signature and Phenotypic Heterogeneity in Hepatocellular Carcinoma.
- Risk factors and clinical outcomes in patients with HCV eradication by direct-acting antivirals: a systematic review and meta-analysis.
- The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma.
- Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study.
- Letter to the editor comments on 'PBK as a Novel Biomarker with Excellent Diagnostic and Prognostic Value in HCC Associated with Immune Infiltration and Methylation'.
- HDAC2-mediated chromatin remodeling drives hepatocellular carcinoma progression: an integrative analysis of computational pathology and multi-transcriptomics.
- ANXA2 in hepatocellular carcinoma: orchestrating tumorigenesis, progression, and therapeutic resistance toward precision targeting.
- Asiaticoside enhances the anti-tumor effect of anti-PDL1 by regulating T cell activity through increasing LCK activity.
- Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma.
- Asparagine synthetase modulates glutaminase inhibitor sensitivity through metabolic reprogramming and serves as a prognostic biomarker in hepatocellular carcinoma.
- Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.
- PART1 facilitates tumorigenesis and inhibits ferroptosis by regulating the miR-490-3p/SLC7A11 axis in hepatocellular carcinoma.
- GLO1 regulates hepatocellular carcinoma proliferation and migration through the cell cycle pathway.
- CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma.
- Integration of single-cell and bulk RNA-sequencing to analyze the heterogeneity of hepatocellular carcinoma and establish a prognostic model.
- Identification of formononetin as the active compound of CR-SR in hepatocellular carcinoma treatment: An integrated approach combining network pharmacology and weighted gene co-expression networks.
- Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy.
- Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.
- PRMT1-mediated arginine methylation promotes YAP activation and hepatocellular carcinoma proliferation.
- Role and therapeutic potential of E3s in the tumor microenvironment of hepatocellular carcinoma.
- Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance.
- Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
- Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
- A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy.
- Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.
- Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
- Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway.
- Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.
- FXR, MRP-1 and SLC7A5: New Targets for the Treatment of Hepatocellular Carcinoma.
- Obesity phenotype induced by high-fat diet promotes diethylnitrosamine (DEN)-induced precancerous lesions by M1 macrophage polarization in mice liver.
- Potential applications of dual haptoglobin expression in the reclassification and treatment of hepatocellular carcinoma.
- Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy.
- TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.
- Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study.
- Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
- A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification.
- Chemical profiling and investigation of molecular mechanisms underlying anti-hepatocellular carcinoma activity of extracts from Polygonum perfoliatum L.
- Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning.
- The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
- External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
- Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
- FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.
- Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.
- Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period.
- T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.
- Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo.
- Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals.
- A commentary on 'Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies' [Int J Surg 105 (2022) 106821].
- Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.
- Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.
- Deciphering the tumour immune microenvironment of hepatocellular carcinoma.
- Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma.
- A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma.
- α-LA attenuates microcystin-LR-induced hepatocellular oxidative stress in mice through Nrf2-mediated antioxidant and detoxifying enzymes.
- Construction of a diagnostic model for hepatitis B-related hepatocellular carcinoma using machine learning and artificial neural networks and revealing the correlation by immunoassay.
- Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?
- THRSP identified as a potential hepatocellular carcinoma marker by integrated bioinformatics analysis and experimental validation.
- Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.
- CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.
- Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma.
- LRFNet: A deep learning model for the assessment of liver reserve function based on Child-Pugh score and CT image.
- Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma.
- Roles of M6A Regulators in Hepatocellular Carcinoma: Promotion or Suppression.
- Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma.
- Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma.
- Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies.
- Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway.
- PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.
- Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study.
- Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.
- Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma.
- The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.
- The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma.
- Development of a Hepatic VX2 carcinoma model in rabbits using an improved minimally invasive method and evaluation with imaging examinations.
- LncRNA NCK1-AS1 Aggravates Hepatocellular Carcinoma by the miR-22-3p/YARS Axis to Activate PI3K/AKT Signaling.
- Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.
- Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images.
- Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.
- The relationship between NTCP gene varieties and the progress of liver disease after HBV infection: an updated systematic review and meta-analysis.
- The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.
- Inflow vascular occlusion technique versus hemihepatic vascular maneuver in hepatectomy: A systematic review and meta-analysis.
- Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.
- miR-381 Reverses Multidrug Resistance by Negative Regulation of the CTNNB1/ABCB1 Pathway in HepG2/Dox Cells, and the Diagnostic and Prognostic Values of CTNNB1/ABCB1 Are Identified in Patients with LIHC.
- Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
- Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis.
- Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
- FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2.
- Early versus Delayed Hepatectomy for Spontaneously Ruptured Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 39 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在胃癌下全国有 218 家医院列在胃癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文39
- The impact of multidimensional interactions among Helicobacter pylori infection, tumor microenvironment, and gut microbiota on gastric cancer immune response.
- Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.
- Glucose metabolism reprogramming in gastric cancer: Implications for tumor.
- Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer.
- Identification of immunotherapy-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognostic signature in gastric carcinoma.
- Downregulation of PDIA3 inhibits gastric cancer cell growth through cell cycle regulation.
- Deep learning is necessary for safety regulation in predicting malnutrition in gastric cancer patients.
- eIF6 Promotes Gastric Cancer Proliferation and Invasion by Regulating Cell Cycle.
- Dysregulation of systemic immunity and its clinical application in gastric cancer.
- Letter to the Editor for the article 'A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study'.
- Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression.
- Cause of death among gastric cancer survivors in the United States from 2000 to 2020.
- LncRNA RP11-93B14.5 promotes gastric cancer cell growth through PI3K/AKT signaling pathway.
- Circadian rhythm genes contribute to the prognosis prediction and potential therapeutic target in gastric cancer.
- Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing.
- Supradiaphragmatic Gastric Monodermal Teratoma With Bronchus-Like Structures.
- Pulling out the radish without mud: Endoscopic blunt dissection of a gastric submucosal tumor.
- The effect of liver transplantation on gastric cancer: A meta-analysis.
- Gastric cancer incidence trends in China and Japan from 1990 to 2019: Disentangling age-period-cohort patterns.
- miR-199a-3p promotes gastric cancer progression by promoting its stemness potential via DDR2 mediation.
- Giant gastric myxoid epithelioid gastrointestinal stromal tumor.
- Dual-Regulated Mechanism of EZH2 and KDM6A on SALL4 Modulates Tumor Progression via Wnt/β-Catenin Pathway in Gastric Cancer.
- Cd44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor.
- SDPR Inhibits TGF-β Induced Cancer Metastasis Through Fatty Acid Oxidation Regulation in Gastric Cancer.
- Endoscopic Removal of an Embedded Fishbone in the Gastric Antrum.
- Gender authorship trends of gastric cancer in the top journals of gastroenterology: A 20-year perspective.
- Association between blood lipid levels and risk of gastric cancer: A systematic review and meta-analysis.
- FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.
- Reverse rolling-mat type lymph node dissection is the key step to solve the operative difficulties in hand-assisted laparoscopic D2 radical gastrectomy.
- Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA.
- The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer.
- H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.
- Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer.
- Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer.
- Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer.
- Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.
- The Multifaceted Role of Long Non-Coding RNA in Gastric Cancer: Current Status and Future Perspectives.
- Vitamin D suppressed gastric cancer cell growth through downregulating CD44 expression in vitro and in vivo.
- The distinct roles of exosomes in tumor-stroma crosstalk within gastric tumor microenvironment.
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 3 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文20
- KC1036 in ewing sarcoma: mechanistic insights and future directions for a multi-targeted therapeutic strategy.
- Incidence trends, overall survival, and metastasis prediction using multiple machine learning and deep learning techniques in pediatric and adolescent population with osteosarcoma and Ewing's sarcoma: nomogram and webpage.
- Challenges in Diagnosing Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report.
- KIAA1429 as a therapeutic target in osteosarcoma: challenging the linear ferroptosis pathway and evaluating translational hurdles.
- Plasma proteins and osteosarcoma: Mendelian randomization analysis and targeted therapeutic discovery.
- Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.
- Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies.
- Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.
- Investigating the molecular mechanism of Mori Cortex against osteosarcoma by bioinformatics analysis and in vitro experimental.
- Honokiol inhibits human osteosarcoma MG63 cell migration by upregulating FTO and Smad6 to promote autophagy.
- Circular RNA IARS modulates the progression and ferroptosis of osteosarcoma via sponging miR-188-5p from RAB14.
- Tumor-derived microparticles promoted M2-like macrophages polarization to stimulate osteosarcoma progression.
- The Long Noncoding RNA ZEB2-AS1 Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma.
- ITGB3 promotes cisplatin resistance in osteosarcoma tumors.
- Identification of genes contributing to cisplatin resistance in osteosarcoma cells.
- Hox transcript antisense RNA knockdown inhibits osteosarcoma progression by regulating the phosphoinositide 3-kinase/AKT pathway through the microRNA miR-6888-3p/spleen tyrosine kinase axis.
- TGF-β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1α dependent manner.
- Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9).
- Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma.
- Limb-salvage surgery using personalized 3D-printed porous tantalum prosthesis for distal radial osteosarcoma: A case report.
早期论文(2016–2020 年)5
- LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
- Screening candidate microRNA-mRNA network for predicting the response to chemoresistance in osteosarcoma by bioinformatics analysis.
- LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
- The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma.
- The metastasis suppressor gene KISS-1 regulates osteosarcoma apoptosis and autophagy processes.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 2 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
牵头的论文3
- KC1036 in ewing sarcoma: mechanistic insights and future directions for a multi-targeted therapeutic strategy.
- Incidence trends, overall survival, and metastasis prediction using multiple machine learning and deep learning techniques in pediatric and adolescent population with osteosarcoma and Ewing's sarcoma: nomogram and webpage.
- Challenges in Diagnosing Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report.
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
泸州有 1 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文10
- Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.
- The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.
- 18F‑FDG PET/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma.
- Repurposing Metformin in hematologic tumor: State of art.
- Non-crystalline light chain proximal tubular disease associated with Waldenström macroglobulinemia.
- LAMP5 may promote MM progression by activating p38.
- Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.
- The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.
- The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
- Serum metabolomics reveals the effects of accompanying treatment on fatigue in patients with multiple myeloma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
这些数字背后的记录
牵头的论文3
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文3
- Aberrant Brain Networks and Relative Band Power in Patients with Acute Anti-NMDA Receptor Encephalitis: A Study of Resting-State EEG.
- Recurrent anti-NMDAR encephalitis during pregnancy combined with two antibodies positive.
- Systemic lupus erythematosus associated with recurrent anti-NMDA receptor encephalitis during pregnancy.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
其他疾病
肺淋巴管平滑肌瘤病
Lymphangioleiomyomatosis2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 2 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
Alport 综合征
Alport syndrome2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 3 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文3
早期论文(2016–2020 年)5
- Schisandrin B Improves the Renal Function of IgA Nephropathy Rats Through Inhibition of the NF-κB Signalling Pathway.
- Cloning and Expression of H. influenzae 49247 IgA Protease in E. coli.
- Interleukin-17 promotes the production of underglycosylated IgA1 in DAKIKI cells.
- Helicobacter pylori participates in the pathogenesis of IgA nephropathy.
- Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
泸州有 1 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
西南医科大学附属医院
Affiliated Hospital of Southwest Medical University
泸州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR Wikidata
Southwest Medical University; Affiliated Hospital of South West Medical University; Affliated Hospital of Southwest Medical University; First Affiliated Hospital of Southwest Medical University; Affiliated Hospital of SouthWest Medical University; Hospital (T.C.M) Affiliated to Southwest Medical University; Affiliated to Southwest Medical University; Affiliated TCM Hospital of Southwest Medical University